Therapeutic Drug Monitoring

Papers
(The H4-Index of Therapeutic Drug Monitoring is 18. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Dose Individualization of Cefepime for Febrile Neutropenia in Patients With Lymphoma or Multiple Myeloma: Implications for Therapeutic Drug Monitoring64
PEG 400 Ion Suppression in Busulfan Detection by High-Performance Liquid Chromatography—Tandem Mass Spectrometry57
Prospective Validation of a Nomogram for Determining the Optimal Dose of Lamotrigine for Augmentation Therapy in Patients With Treatment-Resistant Depression56
Optimal Practice for Vancomycin Therapeutic Drug Monitoring: Position Statement From the Anti-infectives Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicolo50
Cobicistat as a Potential Booster of Ponatinib and Dasatinib Exposure in a CML Patient: A Case Study48
Gentamicin Assay Considering Both Analytical and Clinical Guidelines: A Square Peg in a Round Hole—Letter to the Editor45
Simultaneous Determination of Rifamycin Antibiotics and Their Active Metabolites in Human Plasma Using UHPLC-MS/MS to Evaluate Their Impact on Target Peak Concentrations: A Short Communication44
Gentamicin Administration in Dialysis Patients: Before or After Hemodialysis?35
Quality Control of Busulfan Plasma Quantitation, Modeling, and Dosing: An Interlaboratory Proficiency Testing Program30
Ceftazidime Plasma Concentrations and Neurotoxicity: The Importance of Therapeutic Drug Monitoring in Patients Undergoing Different Modalities of Renal Replacement Therapy. A Grand Round25
Limited Sampling Strategies Fail to Accurately Predict Mycophenolic Acid Area Under the Curve in Kidney Transplant Recipients and the Impact of Enterohepatic Recirculation24
Relationship Between Amphetamine Concentrations in Saliva and Serum in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder22
Microsampling Devices for Routine Therapeutic Drug Monitoring—Are We There Yet?21
Drug–Drug Interactions With Cyclosporine in the Anti-Hepatitis C Viral PrOD Combination Regimen of Paritaprevir/Ritonavir–Ombitasvir and Dasabuvir in Organ Transplant Recipients With Severe Hepatic Fi20
In Silico Pharmacokinetics Evaluation of Forgiveness for Doravirine and Rilpivirine20
Association of Vancomycin Trough Concentration and Clearance With Febrile Neutropenia in Pediatric Patients20
Designer Benzodiazepines: Effects, Toxicity, and Interactions20
Systematic Critical Review of Genetic Factors Associated with Cisplatin-induced Ototoxicity: Canadian Pharmacogenomics Network for Drug Safety 2022 Update18
Therapeutic Drug Monitoring Consulting Cannot be Ruled out by Model-Informed Precision Dosing18
0.051065921783447